The expression of aphidicolin-induced fragile sites in familial breast cancer patients.
The expression frequency of aphidicolin-induced fragile sites was examined in familial breast cancer patients to determine whether this parameter could be used as a marker of genetic susceptibility in at-risk individuals. No difference was found in expression frequency between the breast cancer patients and a group of normal individuals (p = 0.61). This indicates that the expression frequency of aphidicolin-induced fragile sites is not a suitable marker for assessing genetic susceptibility in familial breast cancer.
Mitchell
E L
EL
CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Manchester, United Kingdom.
Woodhouse
B
B
Birch
J M
JM
Santibanez-Koref
M F
MF
D000230:Adenocarcinoma / Q000235:genetics; D000328:Adult; D000368:Aged; D016590:Aphidicolin / Q000494:pharmacology; D001943:Breast Neoplasms / Q000235:genetics*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000235:genetics*; D002478:Cells, Cultured; D043283:Chromosome Fragile Sites; D002873:Chromosome Fragility; D005260:Female; D006801:Humans; D008875:Middle Aged
D016590:Aphidicolin